- Home
- NCMI vs DMAC Comparison
NCMI vs DMAC Comparison
Compare NCMI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- DMAC
- Stock Information
- Founded
- NCMI 2005
- DMAC 2000
- Country
- NCMI United States
- DMAC United States
- Employees
- NCMI N/A
- DMAC N/A
- Industry
- NCMI Advertising
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- DMAC Health Care
- Exchange
- NCMI Nasdaq
- DMAC Nasdaq
- Market Cap
- NCMI 444.2M
- DMAC 178.0M
- IPO Year
- NCMI 2007
- DMAC N/A
- Fundamental
- Price
- NCMI $4.89
- DMAC $4.25
- Analyst Decision
- NCMI Strong Buy
- DMAC Strong Buy
- Analyst Count
- NCMI 5
- DMAC 2
- Target Price
- NCMI $7.40
- DMAC $8.00
- AVG Volume (30 Days)
- NCMI 631.8K
- DMAC 341.9K
- Earning Date
- NCMI 08-04-2025
- DMAC 08-06-2025
- Dividend Yield
- NCMI 2.45%
- DMAC N/A
- EPS Growth
- NCMI N/A
- DMAC N/A
- EPS
- NCMI N/A
- DMAC N/A
- Revenue
- NCMI $238,300,000.00
- DMAC N/A
- Revenue This Year
- NCMI $8.56
- DMAC N/A
- Revenue Next Year
- NCMI $12.67
- DMAC N/A
- P/E Ratio
- NCMI N/A
- DMAC N/A
- Revenue Growth
- NCMI 42.10
- DMAC N/A
- 52 Week Low
- NCMI $4.12
- DMAC $3.19
- 52 Week High
- NCMI $7.60
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- NCMI 45.33
- DMAC 58.21
- Support Level
- NCMI $4.57
- DMAC $3.58
- Resistance Level
- NCMI $5.02
- DMAC $3.88
- Average True Range (ATR)
- NCMI 0.16
- DMAC 0.26
- MACD
- NCMI 0.01
- DMAC 0.05
- Stochastic Oscillator
- NCMI 51.67
- DMAC 97.74
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.